H. Lundbeck A/S
HLUN-B.CODrugs in Pipeline
18
Phase 3 Programs
12
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Eptinezumab
Migraine
Sertindole
Schizophrenia
Nalmefene
Alcohol Dependence
Desmoteplase
Stroke
Risperidone
Schizophrenia
Brexpiprazole
Sleep Disturbances
Duloxetine
Major Depressive Disorder
Azilect®
Parkinson's Disease
Idalopirdine
Alzheimer's Disease
Gaboxadol
Primary Insomnia
Olanzapine
Schizophrenia
Vortioxetine (Lu AA21004)
Major Depressive Disorder
Lu AF82422
Multiple System Atrophy
Lu AG13909
Cushing's Disease
Zicronapine
Schizophrenia
Lu AG09222
Migraine
Lu AE58054
Alzheimer's Disease
Vortioxetine
Depressive Disorder
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Eptinezumab | Phase 3 | Migraine | - | - |
Sertindole | Phase 3 | Schizophrenia | - | - |
Nalmefene | Phase 3 | Alcohol Dependence | - | - |
Desmoteplase | Phase 3 | Stroke | - | - |
Risperidone | Phase 3 | Schizophrenia | - | - |
Brexpiprazole | Phase 3 | Sleep Disturbances | - | - |
Duloxetine | Phase 3 | Major Depressive Disorder | - | - |
Azilect® | Phase 3 | Parkinson's Disease | - | - |
Idalopirdine | Phase 3 | Alzheimer's Disease | - | - |
Gaboxadol | Phase 3 | Primary Insomnia | - | - |
Olanzapine | Phase 3 | Schizophrenia | - | - |
Vortioxetine (Lu AA21004) | Phase 3 | Major Depressive Disorder | - | - |
Lu AF82422 | Phase 2 | Multiple System Atrophy | - | - |
Lu AG13909 | Phase 2 | Cushing's Disease | - | - |
Zicronapine | Phase 2 | Schizophrenia | - | - |
Lu AG09222 | Phase 2 | Migraine | - | - |
Lu AE58054 | Phase 2 | Alzheimer's Disease | - | - |
Vortioxetine | Phase 2 | Depressive Disorder | - | - |
Frequently asked questions
What is in H. Lundbeck A/S's drug pipeline?→
CatalystAlert tracks 18 drug candidates in H. Lundbeck A/S's (HLUN-B.CO) pipeline across Phase 3, Phase 2. Its lead program is Eptinezumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is H. Lundbeck A/S's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for H. Lundbeck A/S (HLUN-B.CO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track HLUN-B.CO biotech catalysts?→
Add HLUN-B.CO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow H. Lundbeck A/S's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.